Purpose: Melanoma is the cancer with the most rapidly rising incidence rate in Norway. Although exposure to ultraviolet radiation (UVR) is the major environmental risk factor, other factors may also contribute. Antidepressants have cancer inhibiting and promoting side effects, and their prescription rates have increased in parallel with melanoma incidence. Thus, we aimed to prospectively examine the association between use of antidepressants and melanoma by using nation-wide data from the Cancer Registry of Norway, the National Registry, the Norwegian Prescription Database and the Medical Birth Registry of Norway. Patient and Methods: All cases aged 18-85 with a primary cutaneous invasive melanoma diagnosed during 2007-2015 (n=12,099) were matched to population controls 1:10 (n=118,467) by sex and year of birth using risk-set sampling. We obtained information on prescribed antidepressants and other potentially confounding drug use (2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015). Conditional logistic regression was used to estimate adjusted rate ratios (RRs) and 95% confidence intervals (CIs) for the association between overall and class-specific use of antidepressants and incident melanoma. Results: Compared with ≤1 prescription, ≥8 prescriptions of antidepressants overall were negatively associated with melanoma (RR 0.81 CI 0.75-0.87). Class-specific analyses showed decreased RRs for selective serotonin reuptake inhibitors (RR 0.82 CI 0.73-0.93) and mixed antidepressants (RR 0.77 CI 0.69-0.86). The negative association was found for both sexes, age ≥50 years, residential regions with medium and highest ambient UVR exposure, all histological subtypes, trunk, upper and lower limb sites and local disease. Conclusion: Use of antidepressants was associated with decreased risk of melanoma. There are at least two possible explanations for our results; cancer-inhibiting actions induced by the drug and less UVR exposure among the most frequent users of antidepressants. Keywords: antidepressants, melanoma, prescription drugs, pharmacoepidemiology, registrybased
Introduction
The incidence of cutaneous melanoma (hereafter melanoma) is increasing in Caucasian populations worldwide. Since the year 2000, melanoma has become the most rapidly growing malignancy in Norway, 1 which ranks amongst the top five countries worldwide in age-standardized melanoma incidence and mortality rates. 2 Approximately three-quarters of all melanoma cases are estimated to be attributable to ultraviolet radiation (UVR) exposure. 3 However, the development of melanoma is a multifactorial process which also depends on individual susceptibility, including skin sensitivity to UVR and number of nevi. 4 Other factors such as previous melanoma diagnosis, 5 family history of melanoma, 6 body anthropometry, 7 hormonal factors 8 and alcohol consumption 9 have also been implicated.
In addition, a comprehensive European case-control study found that stress, traumatic events and depression were significantly associated with increased melanoma risk. 10 Possible causal associations could result from the biological effects of stress, which promotes cancer development, 11, 12 or from associated use of antidepressants. Over the last decades, prescription of antidepressants has increased in several countries, 13, 14 including in Norway. 15, 16 Results from preclinical studies show both cancer-promoting and inhibiting side effects of antidepressant agents, [17] [18] [19] raising the question of whether the use of such drugs influences cancer risk. Observational studies in humans have examined the associations between antidepressant use and several cancers. Early studies indicated a positive association for some cancers, while the predominant finding in more recent studies indicates a negative association. 18 For melanoma, preclinical studies indicate inhibiting side-effects of antidepressant agents. [20] [21] [22] Though observational population-based studies concerning this relationship appear to be lacking. 23, 24 Thus, in this nationwide case-control study we aimed to prospectively examine the association between use of antidepressants and melanoma development, to assess whether such use might influence the melanoma rate.
Materials and Methods
The study has a nested case-control design and uses nationwide population-based registry data that includes the entire Norwegian population, aged 18-85, in the time period 2004-2015 (3.9 million people). The data were obtained from the Cancer Registry of Norway (CRN), the Norwegian Prescription Database (NorPD), the National Registry and the Medical Birth Registry of Norway. Data were linked using the unique personal identification numbers (PIN) assigned to all Norwegian residents. The study design and data collection have been described in detail previously. 25 
Selecting Cases and Controls
The CRN has recorded cancer diagnoses compulsorily by law since 1953, and the completeness exceeds 98%. 1 We obtained information about all melanoma cases in the age group 18-85 years that were diagnosed with a first primary melanoma during 2007-2015 (n=12,099 classified as selective serotonin reuptake inhibitors (SSRI; N06AB), tricyclic antidepressants (TCAs; N06AA) and other antidepressants (N06AF, N06AG and N06AX). Use of antidepressants from more than one class was defined as mixed use. Use of antidepressants was categorized according to number of prescriptions: ≤1 prescription, 2-7 prescriptions and ≥8 prescriptions. The prescriptions may have been obtained at separate or the same dates. Cumulative dose was quantified for each individual based on the total number of DDDs and categorized as non-users and in quartiles (1-91 DDD; 92-365 DDD; 366-1460 DDD; ≥1461 DDD) for the whole sample, for antidepressants overall and for each class of antidepressant. Duration of use was defined as the time between the first and last prescription for each individual, and categorized as ≤5 years and >5 years.
To reduce the possible impact of reverse causation, prescriptions of antidepressants dispensed within a year prior to the date of diagnosis (cases)/index date (controls) were disregarded, as well as prescriptions dispensed after the diagnosis/index date.
Potential Confounders
Certain drugs that affect skin sensitivity to UVR or immune mechanisms could influence the risk of melanoma. [28] [29] [30] [31] To take use of other drugs into account, information about ever use of immunosuppressive drugs (yes/no), ever use of cardiovascular drugs (yes/no) and >1 prescription dispensed of other drugs (yes/no) were obtained from NorPD. The UVR doses increase from northern to southern Norway. Information about the region of residence was obtained from the CRN (cases) and NorPD (controls) and categorized according to cumulative doses of ambient UVR exposure.
32 First in a five-level variable: northern Norway, central Norway, southwestern Norway, southeast inland, and southeast coast. 7 In addition, we categorized it in a three-level variable as low (northern Norway), medium (western and central Norway) and highest (eastern and southern Norway). 33 Cases and controls without information about the place of residence were excluded (67 cases and 3257 controls). Number of children has been inversely associated with melanoma risk, suggesting a potential role of female sex hormones, 34, 35 or of factors related to parity like socioeconomic status and sunbathing habit. 34 Thus, information about number of children (prior to diagnosis/index date) for all women was obtained from the Medical Birth Registry and categorized as 0, 1-3 and >3 children.
Permission to conduct the study was provided by the Norwegian Data Inspectorate, the Regional Committees for Medical and Health Research Ethics and each of the registries that contributed data.
Statistical Analyses
Conditional logistic regression was used to assess the relation between antidepressant use and melanoma risk. Rate ratios (RRs) with 95% confidence intervals (CIs) were estimated, as the collection of controls was done by risk-set sampling. 36 Stratified analyses were also performed by classes of antidepressant prescribed (SSRI, TCAs, other and mixed). All analyses were adjusted for sex and birth year by design, for use of other drugs and residential ambient UVR region. For women, analyses were conducted with and without adjustment for number of children, but the multivariable results are presented without this additional adjustment, since the difference in results was negligible.
To test for trends in prescription number and cumulative dose, the median of each category was used. We tested for interactions between number of prescriptions and the relevant variables: sex, age at diagnosis/index date, ambient UVR region (in three categories) and number of children (for women only) with a likelihood ratio test. Stratified analyses were directed by prior biological and statistical knowledge. RRs were also estimated for the association between number of antidepressant prescriptions and melanoma, stratified by sex, age at diagnosis/index date and residential ambient UVR exposure. Furthermore, we estimated RRs for the associations between number of antidepressant prescriptions and melanoma site, histological subtype, and clinical stage at diagnosis.
In supplementary analyses, RRs were estimated for the association between melanoma and duration of use with a short (≤5 years) and long (>5 years) timeframe, and for the associations between melanoma subtype and number of prescriptions by antidepressant classes.
All statistical analyses were conducted using the statistical software package R (version 3.5.1). 37 The significance level was set to 5%, and all tests were two-sided.
Results
The final study sample consisted of 130,566 individuals. This included 5985 male and 6114 female melanoma cases diagnosed during 2007-2015 with 58,269 and 60,198 population controls, respectively. The majority of cases and controls were ≥50 years of age and resided in the southern/eastern region of Norway (Table 1) . Most tumors were located at the trunk (47%) and lower limb (24%). SSM was the most common histological subtype (55%), and the majority were diagnosed in a local stage (81%). The overall use of antidepressants was 12% among cases and 14% among controls. Women represented half the proportion of users overall (51% among cases and 51% among controls) but represented a higher proportion in those with ≥8 prescriptions (69% and 66%, respectively) and 2-7 prescriptions (63% and 61%, respectively). The most commonly prescribed antidepressant class was SSRIs (51%), where escitalopram (44%) was the most common drug.
When compared with ≤1 prescription, ≥8 prescriptions of any type of antidepressants were associated with a 19% reduced risk of melanoma with a negative trend ( Table 2) . Analysis stratified by duration of use showed significantly lower risk for 2-7 prescriptions (RR 0.52 95% CI 0.38-0.74) and ≥8 prescriptions (RR 0.79 95% CI 0.72-0.87) among longterm users (>5 years). Significantly lower risk was only found for ≥8 prescriptions (RR 0.82 95% CI 0.74-0.92) among shortterm users (≤5 years) (Supplementary Table S1 ). Analyses stratified by antidepressant classes showed an 18% and 23% lower melanoma risk for persons with ≥8 prescriptions of SSRIs and mixed antidepressants, respectively, compared to ≤1 prescription (Table 2 ). For the class of other antidepressants, a significantly negative trend was seen, despite non-significant effect estimates, while for TCA, no associations were found.
Compared to the lowest quartile of cumulative dose (1-91 DDD), no significant association with melanoma risk was found for increasing quartiles (Table 3) . However, a significant trend was found and non-use (0 DDD) was associated with a 15% increased risk. In addition, a reduced risk was found per increment of 100 DDD overall (P trend 0.001) (not shown). When stratifying by classes of antidepressants, no significant associations were found, except for a 69% increased risk among non-users and a 65% increased risk for a cumulative dose of 92-365 DDD when compared to the lowest DDD quartile of mixed antidepressant use (Table 3) . Compared to ≤1 prescription, those with ≥8 prescriptions of antidepressants had a significantly decreased risk of melanoma for specified tumor sites except the head and neck, other and unspecified sites (Table 4) . Moreover, ≥8 prescriptions were associated with a decreased risk of all melanoma subtypes, with significant negative trends (P trend <0.001 (SSM); 0.017 (NM); 0.013 (other)). Supplementary analyses, stratified by antidepressant classes, showed that ≥8 prescriptions of SSRIs were associated with a decreased risk of SSM (RR 0.81 95% CI 0.69-0.96). Mixed antidepressants were associated with a decreased risk of SSM (RR 0.75 95% CI 0.65-0.87) and NM (RR 0.70 95% CI 0.52-0.94). (Supplementary Table S2 ). Lastly, ≥8 prescriptions of antidepressants were associated with a 21% decreased risk for local stage melanoma, while no associations were found for other stages (Table 4) .
Compared to ≤1 prescription, men and women with ≥8 prescriptions of any antidepressant had 27% and 14% reduced risk of melanoma, respectively (P interaction 0.029) ( Table 5) . No association was found for the youngest age group (<50 years), while a 24% and 21% reduced melanoma risk was found in the age groups 50-69 and ≥70 years, DovePress respectively (P interaction 0.013). In the residential regions with medium and highest ambient UVR, ≥8 prescriptions were associated with a 27% and 18% reduced melanoma risk, respectively, while no association was found in the low UVR region (P interaction 0.379). Analyses using the fivelevel variable of residential ambient UVR exposure gave similar results to that with three-levels (not shown). We found no significant interaction with parity (P interaction 0.248).
Discussion
Based on data from nationwide health registries, we found that ≥8 prescriptions of antidepressants were associated with decreased melanoma risk. Analyses stratified by antidepressant classes showed a significant negative association and trend for SSRIs and mixed antidepressants, as well as a negative trend for the class of other antidepressants. For cumulative dose (DDD), a significant negative trend was found for antidepressant use overall and for SSRIs, despite the effect estimates not supporting a dose-response relationship. The negative association was significant for both sexes, age ≥50 years, in residential regions with medium and highest ambient UVR exposure, all histological subtypes, tumors at trunk, upper and lower limb, and for localized disease at diagnosis. Depression and mood disorders may promote cancer processes through several pathways, 11, 12 though the epidemiological evidence for depression being a risk factor for cancer is not strong. 38 However, a comprehensive European case-control study identified factors of stress, traumatic events and depression as being associated with an increased risk of melanoma. 10 On the other hand, antidepressants treat depression disorders and are also found to normalize the pathway alterations that occur during depression. 11 Preclinical studies have raised the question of whether such drugs can influence cancer risk. The predominant findings indicate cancer-inhibitory actions of antidepressants, although cancer-promoting effects have also been observed. 18, 19 It is worth noting though that such studies vary with regard to design and type of antidepressant. It is suggested that antidepressants may affect pathways which inhibit the malignant cell cycle and activates the immune system in ways that trigger apoptosis in Over the last two decades, an increasing number of observational studies have investigated the association between antidepressants and cancer, mainly focusing on breast, ovarian and colon cancer. Results from the first studies suggested a positive association, but over time, the findings predominantly indicated a negative association (mainly for SSRIs). 18 A previous review found that shortterm and/or low-dose antidepressant use increased the risk of breast and ovarian cancer. 42 More recently however, a prospective cohort study, within the Nurses' Health Study (USA), found no associations for breast cancer 43 and a nationwide registry-based case-control study from Denmark found a negative association between SSRIs and epithelial ovarian cancer. 44 To our knowledge, this is the first observational study investigating the relation between antidepressants and melanoma risk. Our results are in line with the cancer-inhibiting properties exhibited by these drugs in pre-clinical studies, including the more recent observational studies of other cancer types. The different results observed across antidepressant classes however, may be due to different action pathways inherent to each drug 45 but may also result from small groups and weakened power in stratified analyses. We found a significant negative association for both sexes, although it seemed to be stronger for men than for women. Reproductive factors and female sex hormones are suggested to play a role in melanoma development. 34, 35 A recent population-based cohort study of Norwegian women found no association between reproductive factors and melanoma risk 46 and neither did our analyses. Adjusting for number of children (for women only) did not influence the estimates. Regarding menopausal hormone use, a nationwide cohort study based on Finnish data recently reported a significant positive association between menopausal estrogen therapy and melanoma risk. 47 In our analyses, we have adjusted for other drug use, however, we were not able to separate estrogen use from other drugs. The elevated risk observed in non-users, compared to the lowest cumulative dose (DDD 1-91), weakens the hypothesis that drug effects explain our findings. Patients with depression are less active in everyday social life, 48 which might also include activities involving UVR exposure. As far as we know, neither depression nor use of antidepressants has been associated with altered habits of outdoor activity and reduced UVR exposure. Increased use of indoor tanning has been observed, 49, 50 although such studies only involve age groups <50 years. If a decrease in social functioning among patients with depression leads to a reduction in UVR exposure, the potential difference in UVR exposure between the healthy and the depressed should be more distinct in areas with higher ambient UVR exposure, which is in line with our result. Thus, our data do not support the use of antidepressants as a preventive measure against melanoma.
In analyses by duration of use, the negative association was significant for both user categories among long-term users (>5 years), but only for the highest user category among short-term users (<5 years). Such results are in line with potential cancer-inhibiting actions induced by longterm use or a considerable short-term use of antidepressants. However, if the most depressed are those most affected socially, and represent those treated over a longer timeframe or have a higher number of prescription over a shorter timeframe, then reduced UVR exposure could be a possible explanation.
The main strengths of this study include the use of complete and high-quality data, collected from nationwide registries with mandatory reporting. This approach eliminated selection and recall bias and ensured detailed information about invasive melanoma diagnoses and drug use. Only pre-diagnostic prescriptions of antidepressants were included, and all prescriptions given the year before diagnosis/index date were removed for cases and controls, respectively. Primary non-adherence is not an issue since only information pertaining to drug dispensation and purchase by patients is recorded in the NorPD, and are more indicative of use than prescriptions alone. 51 In addition, the agreement between filled prescriptions data and selfreported antidepressant medication is reported to be good. 52 There are also limitations when interpreting the results of this study. We had no information about individual UVR exposure, such as recreational sun exposure, sunburns (as a marker of severe acute UV exposure episodes) and indoor tanning. As the latency time between drug exposure and melanoma diagnosis is uncertain, the followup time might have been insufficient to reveal the true association between use of antidepressants and melanoma risk. Underlying indications for drug use and comorbidities that influence the risk of melanoma may have introduced potential confounding by indication. Although we have adjusted for use of other drug types, we cannot exclude the possibility that different indications for different antidepressant could have produced different estimates for the drug classes. Furthermore, different indications may be related to other relevant factors (eg, obesity, socioeconomic factors, hormone use, and alcohol consumption). Unfortunately, we lack information about such potentially confounding factors. In addition, differences in healthcare usage may influence our results, although adjustment for use of other drugs could act as an indicator for this. While the majority of people in Norway live in the southern/ eastern regions, we cannot rule out that access to healthcare and prescription practices may vary between regions.
Conclusions
The negative associations observed between antidepressant use and melanoma risk can result from at least two possible explanations: cancer-inhibiting actions induced by the drug and less UVR exposure among the most frequent users of antidepressants, compared to non-users. To investigate this further, studies with individual information about UVR exposure and indication for drug use are required.
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